Back to search

Statins and the primary prevention of cardiovascular events

Data up to Jan 2025

Published2006
Citations30
References44

Total Citations Per Year

Abstract

References (44)

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study

2017 • 28,714 citations

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

2001 • 24,089 citations

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

1995 • 7,378 citations

The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020.

1996 • 7,011 citations

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

2004 • 6,926 citations

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

2002 • 6,780 citations

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

2005 • 6,633 citations

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels

1998 • 5,293 citations

Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes

2003 • 4,328 citations

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

2003 • 3,816 citations

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

2004 • 3,776 citations

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

1995 • 3,524 citations

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

2002 • 3,347 citations

C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events

2003 • 2,283 citations

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

1990 • 2,192 citations

Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease

2001 • 1,999 citations

Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?

2014 • 1,880 citations

Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated With the Metabolic Syndrome

2005 • 1,657 citations

A strategy to reduce cardiovascular disease by more than 80%

2003 • 1,553 citations

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

2001 • 1,537 citations

Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study

2003 • 1,509 citations

Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

2002 • 1,311 citations

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

1999 • 973 citations

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

2001 • 783 citations

Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults

2004 • 755 citations

Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?

2004 • 648 citations

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

2004 • 543 citations

Optimal low-density lipoprotein is 50 to 70 mg/dl

2004 • 465 citations

Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

2003 • 427 citations

Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes

2004 • 324 citations

Metabolic Syndrome: Risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial

2006 • 153 citations

Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome

2003 • 152 citations

Cardiovascular Disease in U.S. Patients With Metabolic Syndrome, Diabetes, and Elevated C-Reactive Protein

2005 • 145 citations

Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease

1998 • 145 citations

Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III.

2001 • 121 citations

Metabolic Syndrome

2006 • 120 citations

Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease

2004 • 107 citations

Statin and β-Blocker Therapy and the Initial Presentation of Coronary Heart Disease

2006 • 86 citations

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Ridker PM, Buring JE, Cook NR, Rifai NR. Circulation 2003; 107: 391-397.

2003 • 40 citations

Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III Guidelines

2005 • 29 citations

Association of the Metabolic Syndrome With Early Coronary Disease in Families With Frequent Myocardial Infarction

2006 • 19 citations

Post-hospitalization management of high-risk coronary patients

2000 • 10 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...